Cargando…
Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?
Interstitial lung disease (ILD) is a severe and frequent manifestation of connective tissue diseases (CTD). Due to its debilitating potential, it requires serious evaluation and treatment. The prevalence of ILD in systemic lupus erythematosus (SLE) is still controversial. Therefore, in order to esta...
Autores principales: | Richter, Patricia, Cardoneanu, Anca, Dima, Nicoleta, Bratoiu, Ioana, Rezus, Ciprian, Burlui, Alexandra Maria, Costin, Damiana, Macovei, Luana Andreea, Rezus, Elena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253395/ https://www.ncbi.nlm.nih.gov/pubmed/37298342 http://dx.doi.org/10.3390/ijms24119388 |
Ejemplares similares
-
Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?
por: Richter, Patricia, et al.
Publicado: (2022) -
Cytokines in Systemic Lupus Erythematosus—Focus on TNF-α and IL-17
por: Richter, Patricia, et al.
Publicado: (2023) -
Adult-Onset Still’s Disease—A Complex Disease, a Challenging Treatment
por: Macovei, Luana Andreea, et al.
Publicado: (2022) -
Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6?
por: Cardoneanu, Anca, et al.
Publicado: (2022) -
Non-Traditional Pro-Inflammatory and Pro-Atherosclerotic Risk Factors Related to Systemic Lupus Erythematosus
por: Richter, Patricia, et al.
Publicado: (2022)